BioNTech SE - ADR vs JetBlue Airways Corporation — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while JetBlue Airways Corporation trades at $5.8 (market cap $2.19B). The key difference: BioNTech SE - ADR is far larger — about 10.6× JetBlue Airways Corporation's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | JBLU | |
|---|---|---|
Market Cap | $23.31B | $2.19B |
Sector | Health | Industrials |
52-Week High | $119.34 | $6.46 |
52-Week Low | $83.89 | $4.03 |
Enterprise Value | $6.60B | $9.56B |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
JetBlue (JBLU) trades at $5.855, up 3.81% today, with a bullish technical signal from moving averages but mixed earnings history including a recent Q2 2026 beat. The company shows negative profitability with a net income margin of -9.32% and ROE of -44.36%, while valuation ratios like P/S of 0.23 suggest potential undervaluation. Recent news highlights analyst downgrades and operational challenges from high fuel costs, alongside strategic initiatives like new fare structures and lounge awards.
Outlook remains cautious due to persistent losses and external pressures, but cost management and revenue growth initiatives offer recovery potential. Key risks include fuel price volatility and competitive intensity, while analyst consensus is neutral with a $5.18 price target slightly below current levels, indicating limited near-term upside amid ongoing fundamental headwinds.
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →